
Opinion|Videos|April 11, 2025
Treatment of Severe Alopecia Areata with JAK Inhibitors
Author(s)Arash Mostaghimi, MD, MPH, Brett King, MD, PhD
A panelist discusses how their traditional treatment approach for severe alopecia areata typically involved a stepped care pathway beginning with topical and intralesional steroids before progressing to systemic immunosuppressants or immunotherapy, which often yielded inconsistent, temporary, or incomplete hair regrowth results, leaving significant unmet needs for treatments that could provide sustained efficacy, acceptable safety profiles, and therapies specifically developed for this condition rather than repurposed from other dermatologic disorders.
Advertisement
Episodes in this series

- For patients diagnosed with severe alopecia areata, what has traditionally been your treatment approach?
- In your experience, how did these traditional approaches work for managing alopecia areata?
- What unmet treatment needs remain?
Advertisement
Related to this article

The FDA updated the risankizumab label to make pretreatment TB evaluation a matter of clinical judgment across all indications, including psoriasis.

Phase 2 and 3 data show difamilast 1% ointment improved severity and itch within 1 week in adults and children with mild to moderate atopic dermatitis.

Final VALUE data show fewer drug changes with risankizumab vs other biologics over 37 months in patients with psoriasis and comorbid psoriatic arthritis.

Stay updated with the latest healthcare breakthroughs, including new TRANSCEND-T2D-2 data and FDA actions.

The plasmid DNA immunotherapy Voceryq gained FDA accelerated approval after 27% of RRP-001 patients needed no surgery for 12 months.

IgAN late-breakers led the meeting, alongside new data on aspirin, dialysis access, donor pregnancy, potassium, and depression.

Experts discuss remibrutinib, the first FDA-approved therapy for symptomatic dermographism: RemIND data, bleeding counseling, and where it fits in practice
Advertisement
Advertisement
Trending on HCPLive
1
Cardiac Health Indicators Improve Following CCM Implantation in Heart Failure
2
Sarcoidosis Care Starts With Inflammation vs Fibrosis: Rohit Gupta, MD
3
ASN Kidney Week 2026 Recap: 8 Key Updates in Kidney Disease to Know
4
HCPLive Five at CHEST 2026
5

